[1] Bajaj JS, O'Leary JG, Lai JC, et al. Acute-on-Chronic Liver Failure Clinical Guidelines. Am J Gastroenterol,2022,117(2):225-252.
[2] 郭庆红, 龙岩君, 蒲春文, 等. 微小RNA在乙型肝炎病毒相关慢加急性肝衰竭中的研究进展. 兰州大学学报(医学版),2015,41(04):62-6+71.
[3] Casulleras M, Zhang IW, López-Vicario C, et al. Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure. Cells,2020,9(12).
[4] 陈渊渊, 孟忠吉. 系统性炎症在慢加急性肝衰竭发病机制中的作用. 中西医结合肝病杂志,2021,31(10):951-955.
[5] Khanam A, Kottilil S. Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management. Front MED,2021,8:752875.
[6] Engelmann C, Clària J, Szabo G, et al. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol,2021,75 Suppl 1:S49-66.
[7] 刘贵章, 夏琴, 冯霞, 等. 血清降钙素原及炎症指标联合MELD评分对慢加急性肝衰竭患者短期预后的预测价值. 白求恩医学杂志,2019,17(06):532-534.
[8] Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology,2013, 144(7):1426-37,37.e1-9.
[9] 谭立明, 蒙仪妹, 隆婷婷, 等. 降钙素原、D-二聚体、C-反应蛋白对慢加急性肝衰竭患者并发感染的临床意义. 实用医学杂志,2018,34(03):410-415.
[10] 陈小琴, 林志刚. 血清PCT、CRP、PTA联合MELD评分系统预测 ACLF患者短期预后的价值. 医学理论与实践,2021,34(23):4164-4166.
[11] 郑义彬, 王爱国, 陈冲, 等. 乙型肝炎病毒相关慢加急性肝衰竭患者血清PCT与肝功能参数的相关性分析. 中西医结合肝病杂志,2021,31(12):1130-1133.
[12] Wu W, Yan H, Zhao H, et al. Characteristics of systemic inflammation in hepatitis B-precipitated ACLF: Differentiate it from No-ACLF. Liver Int,2018,38(2):248-257.
[13] 刘潇, 张珊, 陈文慧, 等. 中性粒细胞胞外诱捕网形成机制及其在肝脏疾病中的作用. 医学综述,2021,27(08):1469-1474.
[14] Wu W, Sun S, Wang Y, et al. Circulating Neutrophil Dysfunction in HBV-Related Acute-on-Chronic Liver Failure. Front Immunol,2021,12:620365.
[15] Sun J, Guo H, Yu X, et al. Evaluation of prognostic value of neutrophil-to-lymphocyte ratio in patients with acute-on-chronic liver failure or severe liver injury from chronic HBV infection. Eur J Gastroenterol Hepatol,2021,33(1S Suppl 1):e670-80.
[16] Cai J, Wang K, Han T, et al. Evaluation of prognostic values of inflammation-based makers in patients with HBV-related acute-on-chronic liver failure. Medicine,2018,97(46):e13324.
[17] Bernsmeier C, Cavazza A, Fatourou EM, et al. Leucocyte ratios are biomarkers of mortality in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. Aliment Pharmacol Ther,2020,52(5):855-865.
[18] Liu XY, He X, Cai M, et al. Prognostic Value of Complete Blood Cell Count-Derived Inflammatory Markers in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Clin Lab,2021,67(10).
[19] Qiang L, Qin J, Sun C, et al. A novel predictive model based on inflammatory markers to assess the prognosis of patients with HBV-related acute-on-chronic liver failure: a retrospective cohort study. BMC Gastroenterol,2020,20(1):301.
[20] 严汀华, 谢雪华, 江金华, 等. NLR在乙肝相关慢加急性肝衰竭诊断及预后预测价值. 承德医学院学报,2021,38(05):379-382.
[21] 段斌炜, 李娟, 张宫铭, 等. 乙肝相关慢加急性肝衰竭患者肝移植术后影响生存的危险因素分析. 国际外科学杂志,2022,49(01):40-6,F4.
[22] 秦娇, 强丽, 陈文, 等. 红细胞分布宽度可作为乙型肝炎相关慢加急性肝衰竭患者短期死亡的独立预测因子. 南方医科大学学报,2018,38(11):1354-1359.
[23] Tian Z, Yao N, Wu Y, et al. Association between plasma level of superoxide dismutase and survival of patients with acute-on-chronic liver failure. BMC Gastroenterol,2022,22(1):50.
[24] 苏亚勇, 徐成润, 郭永木, 等. 慢加急性乙型肝炎肝衰竭患者死亡危险因素和预后评分模型的构建. 实用肝脏病杂志,2021,24(03):391-394.
[25] Zhang ZQ, He G, Luo ZW, et al. Individual mortality risk predictive system of patients with acute-on-chronic liver failure based on a random survival forest model. Chin Med J,2021,134(14):1701-8.
[26] Khodadi E. Platelet Function in Cardiovascular Disease: Activation of Molecules and Activation by Molecules. Cardiovasc Toxicol,2020,20(1):1-10.
[27] Xu X, Hou Z, Xu Y, et al. The dynamic of platelet count as a novel and valuable predictor for 90-day survival of hepatitis B virus-related acute-on-chronic liver failure patients. Clin Res Hepatol Gastroenterol,2021,45(2):101482.
[28] 司诺, 刘芳, 刘磊, 等. PLT水平及PLT参数对慢加急性肝衰竭患者预后的影响. 临床肝胆病杂志,2022,38(02):381-386.
[29] 强丽, 秦娇, 孙长峰, 等. 基于炎症因子中性粒/淋巴细胞比值与红细胞分布宽度的预测模型对乙肝相关慢加急性肝衰竭的预后评估. 重庆医科大学学报,2021,46(03):317-24.
[30] 李思睿, 王军, 张宏玲, 等. 肝硬化并发门静脉血栓的影响因素及预测因子研究进展. 山东医药,2021, 61(12):89-93.
[31] 徐英, 黄小平, 陈丽, 等. 平均血小板体积对HBV相关慢加急性肝衰竭预后的评估价值. 临床肝胆病杂志,2020,36(10):2199-2202.
[32] TAN NH, CHEN B, PENG J, et al. Treg/Th17 Cell Balance in Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure at Different Disease Stages. Biomed Res Int,2021,2021.
[33] 朱立娜, 唐源, 黄初军, 等. 慢加急性肝衰竭患者血清白介素-17、白介素-6及肿瘤坏死因子-α的检测分析. 中国当代医药,2019,26(36):44-46.
[34] 诸海军, 万健, 孙莲娜, 等. WBC、IL-6及NLR值对慢加急性肝衰竭患者的早期预警价值. 肝脏,2019,24(09):1076-1078.
[35] 郄永强, 周会杰. 血清IL-23对慢性乙型肝炎肝功能衰竭患者生存状况的影响. 肝脏,2019,24(03):274-277.
[36] Wang N, Fan YC, Xia HH, et al. Plasma interleukin-10 predicts short-term mortality of acute-on-chronic hepatitis B liver failure. Aliment Pharmacol Ther,2016,43(11):1208-1221.
[37] Yang L, Zhang Q, Song J, et al. Interleukin-35 Suppresses CD8(+)T Cell Activity in Patients with Viral Hepatitis-Induced Acute-on-Chronic Liver Failure. Dig Dis Sci,2020,65(12):3614-3623.
[38] Schulz MS, Gu WY, Schnitzbauer AA, et al. Liver Transplantation as a Cornerstone Treatment for Acute-On-Chronic Liver Failure. Transpl Int,2022. |
